Pharmaceutical Manufacturing
Grand Pharmaceutical Group Limited (stock code: 00512.HK), abbreviated as “Grand Pharma”, is an international pharmaceutical company of technological innovation, integrating pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision intervention diagnosis and treatment technology and biotechnology.
In 2002, Grand Pharma completed the change of shareholding structure and was indirectly listed in Hong Kong. Our Group has more than 30 member companies, focusing on various pharmaceutical fields including respiratory and severe disease anti-infection, tumor, cerebro-cardiovascular emergency, ophthalmology, cerebro-cardiovascular precision intervention diagnosis and treatment, nuclear medicine anti-tumor and high-quality amino acid.
Our Group focuses on the needs of patients, adapts to the market development and take technological innovation as the driving force. In recent years, our Group has successively distributed a series of innovative pharmaceutical products and medical devices products with global markets including the United States, Australia, Germany, Belgium and other countries. Our Group also established the collaborations with world-leading pharmaceutical enterprises, universities and research institutions, and diversified the product pipeline in medical therapeutic fieldd. Currently, our Group already has 5 R&D technology platforms and 9 R&D centers worldwide.